FI107159B - Menetelmä askomysiinimakrolidijohdannaisten valmistamiseksi - Google Patents

Menetelmä askomysiinimakrolidijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI107159B
FI107159B FI942444A FI942444A FI107159B FI 107159 B FI107159 B FI 107159B FI 942444 A FI942444 A FI 942444A FI 942444 A FI942444 A FI 942444A FI 107159 B FI107159 B FI 107159B
Authority
FI
Finland
Prior art keywords
formula
hydroxy
compound
och
substituents
Prior art date
Application number
FI942444A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI942444A (fi
FI942444A0 (fi
Inventor
A R C Murty Bulusu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939310969A external-priority patent/GB9310969D0/en
Priority claimed from GB939310975A external-priority patent/GB9310975D0/en
Priority claimed from GB939312590A external-priority patent/GB9312590D0/en
Priority claimed from GB939313553A external-priority patent/GB9313553D0/en
Priority claimed from GB939319618A external-priority patent/GB9319618D0/en
Priority claimed from GB939319617A external-priority patent/GB9319617D0/en
Priority claimed from GB939326045A external-priority patent/GB9326045D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI942444A0 publication Critical patent/FI942444A0/fi
Publication of FI942444A publication Critical patent/FI942444A/fi
Application granted granted Critical
Publication of FI107159B publication Critical patent/FI107159B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Color Printing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI942444A 1993-05-27 1994-05-25 Menetelmä askomysiinimakrolidijohdannaisten valmistamiseksi FI107159B (fi)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
GB9310975 1993-05-27
GB939310969A GB9310969D0 (en) 1993-05-27 1993-05-27 Organic compounds
GB939310975A GB9310975D0 (en) 1993-05-27 1993-05-27 Organic compounds
GB9310969 1993-05-27
GB939312590A GB9312590D0 (en) 1993-06-18 1993-06-18 Organic compounds
GB9312590 1993-06-18
GB9313553 1993-07-01
GB939313553A GB9313553D0 (en) 1993-07-01 1993-07-01 Organic compounds
GB9319617 1993-09-23
GB939319618A GB9319618D0 (en) 1993-09-23 1993-09-23 Organic compounds
GB939319617A GB9319617D0 (en) 1993-09-23 1993-09-23 Organic compounds
GB9319618 1993-09-23
GB939326045A GB9326045D0 (en) 1993-12-21 1993-12-21 Organic compounds
GB9326045 1993-12-21

Publications (3)

Publication Number Publication Date
FI942444A0 FI942444A0 (fi) 1994-05-25
FI942444A FI942444A (fi) 1994-11-28
FI107159B true FI107159B (fi) 2001-06-15

Family

ID=27562893

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942444A FI107159B (fi) 1993-05-27 1994-05-25 Menetelmä askomysiinimakrolidijohdannaisten valmistamiseksi

Country Status (24)

Country Link
US (1) US5493019A (pt)
EP (1) EP0626385B1 (pt)
JP (1) JP3076724B2 (pt)
CN (1) CN1048495C (pt)
AT (1) ATE252105T1 (pt)
AU (1) AU682499B2 (pt)
CA (1) CA2124260C (pt)
CY (1) CY2523B1 (pt)
CZ (1) CZ286157B6 (pt)
DE (1) DE69433234T2 (pt)
DK (1) DK0626385T3 (pt)
ES (1) ES2208651T3 (pt)
FI (1) FI107159B (pt)
HK (1) HK1011684A1 (pt)
HU (1) HU218919B (pt)
IL (1) IL109775A (pt)
MY (1) MY110603A (pt)
NO (1) NO308302B1 (pt)
NZ (1) NZ260596A (pt)
PH (1) PH30420A (pt)
PT (1) PT626385E (pt)
RU (1) RU2130460C1 (pt)
SI (1) SI0626385T1 (pt)
SK (1) SK281541B6 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0786986B1 (en) 1994-10-26 2002-03-20 Novartis AG Use of an unsaturated fatty alcohol
AU748334B2 (en) 1997-10-16 2002-05-30 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
ATE464900T1 (de) 1998-03-26 2010-05-15 Astellas Pharma Inc Retardpräparat mit makroliden wie tacrolimus
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US6121257A (en) * 1999-03-31 2000-09-19 Abbott Laboratories Sulfamate containing macrocyclic immunomodulators
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
WO2004009056A1 (en) 2002-07-23 2004-01-29 Novartis Ag Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
CA2552305A1 (en) * 2003-12-30 2005-07-14 Astellas Pharma Inc. Use of macrolides for treating or preventing airflow obstruction
GT200500282A (es) 2004-10-12 2006-05-04 Heteroatomos conteniendo compuestos triciclicos.
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US9062074B2 (en) * 2009-07-15 2015-06-23 Cti Biopharma Corp. (9E)-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2.5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
EP3246036B1 (en) 2014-10-28 2021-10-13 Koushi Yamaguchi Medicine for improving pregnancy-induced hypertension syndrome
AU2019318035A1 (en) 2018-08-10 2021-03-04 Koushi Yamaguchi Therapeutic agent for humoral immunity-related diseases in materno-fetal relationship
EP3900729A4 (en) 2018-12-18 2022-09-07 Koushi Yamaguchi AGENT FOR TREATING INFERTILITY, RECURRENT MISSORAGE AND IMPROVING PREGNANCY
EP3914599A4 (en) * 2019-01-23 2022-10-19 The Johns Hopkins University NON-IMMUNOSUPPRESSIVE ANALOGS OF FK506 AND ASSOCIATED USE
WO2022139524A1 (ko) * 2020-12-24 2022-06-30 서울대학교산학협력단 신규 fk506 유도체 및 이를 포함하는 발모 촉진용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0078235A3 (de) * 1981-10-23 1983-06-29 Ciba-Geigy Ag Dihalogenierte Steroide
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CH677448A5 (pt) * 1987-11-09 1991-05-31 Sandoz Ag
EP0385936A1 (de) * 1989-02-27 1990-09-05 Ciba-Geigy Ag Peptidlacton und derivate davon, Verfahren zu ihrer Herstellung und Mittel zur Ausführung des Verfahrens
IE910847A1 (en) * 1990-03-13 1991-09-25 Fisons Plc Immunosuppressive macrocyclic compounds
CA2051872A1 (en) * 1990-09-24 1992-03-25 Kevin M. Byrne Directed biosynthesis process for prolyl-immunomycin
GB2249787A (en) * 1990-11-19 1992-05-20 Fujisawa Pharmaceutical Co Lactone compounds
WO1992013862A1 (en) * 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
JP3036923B2 (ja) * 1991-10-28 2000-04-24 理化学研究所 デプシペプチドａ、ｂその製造方法、並びに抗ウイルス剤及び抗菌剤
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them

Also Published As

Publication number Publication date
NZ260596A (en) 1995-10-26
AU6331794A (en) 1994-12-01
HU9401582D0 (en) 1994-08-29
DE69433234D1 (de) 2003-11-20
IL109775A (en) 1999-07-14
NO941936L (no) 1994-11-28
HUT71396A (en) 1995-11-28
FI942444A (fi) 1994-11-28
CA2124260A1 (en) 1994-11-28
SK281541B6 (sk) 2001-04-09
ATE252105T1 (de) 2003-11-15
CN1099756A (zh) 1995-03-08
SI0626385T1 (en) 2004-02-29
JPH06340672A (ja) 1994-12-13
HK1011684A1 (en) 1999-07-16
IL109775A0 (en) 1994-08-26
PH30420A (en) 1997-05-09
EP0626385B1 (en) 2003-10-15
CY2523B1 (en) 2006-02-08
RU2130460C1 (ru) 1999-05-20
NO308302B1 (no) 2000-08-28
EP0626385A1 (en) 1994-11-30
HU218919B (hu) 2000-12-28
DE69433234T2 (de) 2004-08-05
SK61194A3 (en) 1995-02-08
DK0626385T3 (da) 2004-02-16
CA2124260C (en) 2007-04-17
JP3076724B2 (ja) 2000-08-14
NO941936D0 (no) 1994-05-25
ES2208651T3 (es) 2004-06-16
CZ286157B6 (cs) 2000-01-12
CN1048495C (zh) 2000-01-19
MY110603A (en) 1998-08-29
AU682499B2 (en) 1997-10-09
US5493019A (en) 1996-02-20
FI942444A0 (fi) 1994-05-25
PT626385E (pt) 2004-03-31
CZ129594A3 (en) 1995-01-18

Similar Documents

Publication Publication Date Title
FI107159B (fi) Menetelmä askomysiinimakrolidijohdannaisten valmistamiseksi
JP3725901B2 (ja) ラパマイシンヒドロキシエステル、それらの製造方法、および、それらを含有する医薬組成物
US5373014A (en) Rapamycin oximes
US5387680A (en) C-22 ring stabilized rapamycin derivatives
US5484790A (en) Carbamates of rapamycin
KR100351222B1 (ko) 매크로사이클릭 면역 조절제 및 이의 제조방법
US7342011B2 (en) Rifamycin analogs and uses thereof
EP0613901A2 (en) Macrocyclic immunomodulators
HU211135A9 (en) Heteroatoms-containing tricyclic compounds
CA2405593C (en) Macrolides
JP2002540209A (ja) スルファメート含有大環状免疫調節剤
KR100317009B1 (ko) 테트라하이드로피란유도체
JP2562001B2 (ja) マクロライド系抗生物質の２−アミノ糖誘導体
JP2563080B2 (ja) マクロライドの糖誘導体
AU679854C (en) Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them
PL176409B1 (pl) Pochodne tetrahydropiranu, sposób ich wytwarzania i zawierająca je kompozycja farmaceutyczna
MXPA01009935A (es) Inmunomoduladores macorciclicos que contienen fosfato.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

MM Patent lapsed